『Dr. David Sinclair: The First Human Trial of an Age-Reversal Therapy』のカバーアート

Dr. David Sinclair: The First Human Trial of an Age-Reversal Therapy

Dr. David Sinclair: The First Human Trial of an Age-Reversal Therapy

無料で聴く

ポッドキャストの詳細を見る
A Note from James:I’ve been obsessed with anti-aging and longevity science for a long time. I’ve had many longevity researchers on the podcast, but this episode feels different because something we’ve been discussing for years has now moved into human trials.David Sinclair first came on the show in 2019, when his book Lifespan was published. He’s a professor of genetics at Harvard Medical School, and that first conversation changed how I lived. I started experimenting with intermittent fasting, paid much more attention to sleep, and began researching many of the supplements and lifestyle changes he discussed.But the most important idea David talked about wasn’t a supplement. It was the possibility of reversing cellular age using Yamanaka factors—genes that can reset the instructions cells use to function. At the time, nobody knew whether this could be done safely without causing cancer or making cells lose their identities.Now, a therapy based on three of those factors has entered its first human clinical trial. The initial target is age-related damage to the optic nerve, including open-angle glaucoma and non-arteritic anterior ischemic optic neuropathy. The trial is designed primarily to evaluate safety, but researchers will also measure visual function.David explains how this technology worked in mice and nonhuman primates, why the eye was chosen as the first organ, and how the same approach might eventually be applied to the liver, lungs, joints, skin, and brain.We also cover the practical questions people always ask him: NMN, NAD, metformin, berberine, testosterone, growth hormone, diet, fasting, sleep, exercise, and what David himself has started—or stopped—taking.This is still experimental science. Nobody yet knows whether the animal results will translate into meaningful benefits for humans. But for the first time, researchers are beginning to test that question directly.About Lifespan: Dr. David Sinclair founded Lifespan to deliver clear, science-backed health insights that help people live longer, more vibrant lives.He's now building the world's largest community dedicated to extending human longevity well beyond today’s limits. Join early access at lifespan.com. New episodes of Lifespan with Dr. David Sinclair -- the #1 health and wellness podcast in its first season -- are now available on YouTube, Spotify, Apple Podcasts, and Lifespan.com.Episode Description:For years, longevity researchers have looked for ways to slow the biological processes associated with aging. Dr. David Sinclair and his collaborators are now testing a more ambitious possibility: whether damaged human cells can be restored to a younger, more functional state.The experimental therapy, ER-100, uses controlled expression of three transcription factors—OCT4, SOX2, and KLF4, collectively known as OSK. These are three of the four Yamanaka factors originally used to transform adult cells into pluripotent stem cells.Turning on all four factors can erase too much of a cell’s identity and has produced tumors and fatal outcomes in animal experiments. Sinclair’s team found that removing one factor, c-MYC, allowed cells to regain younger patterns of gene expression without completely returning to a stem-cell state.In preclinical studies, OSK restored youthful epigenetic patterns, promoted optic-nerve regeneration, and reversed vision loss in mouse models. Life Biosciences, a company Sinclair co-founded, has now moved the technology into a first-in-human Phase 1 trial involving people with open-angle glaucoma or non-arteritic anterior ischemic optic neuropathy.David explains how the therapy is delivered directly into the eye and activated using doxycycline, allowing clinicians to control when and for how long the genes are expressed. He also describes the development path that could follow if the treatment proves safe, including therapies targeting the liver and other organs, as well as future medicines that may reproduce similar effects without gene delivery.The conversation then turns to interventions available today. David distinguishes between promising research and claims that have moved ahead of the evidence, discussing NMN, injected NAD, growth hormone, testosterone, taurine, nattokinase, metformin, berberine, and nootropics.Throughout the episode, he emphasizes that no supplement has been shown to reproduce the effects researchers are attempting to achieve through partial epigenetic reprogramming—and that many of the most dramatic claims circulating online remain unsupported.Editorial Note:ER-100 is an investigational therapy. Authorization to begin a clinical trial does not mean the treatment has been proven safe or effective, nor has it been approved for clinical use.The Phase 1 study is primarily evaluating safety and tolerability, with additional measurements of visual function. Results from mice and nonhuman primates do not establish that the therapy will restore vision or reverse biological ...
adbl_web_anon_alc_button_suppression_t1
まだレビューはありません